Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) announced that recently, the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd. received the “Notice of Acceptance” issued by the State Drug Administration. The company's application for marketing licensing of injectable Ruikang trastuzumab was accepted and included in the priority review process.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.